Weekly CHOP for the treatment of advanced intermediate and high-grade non-Hodgkin's lymphoma.
Between January 1981 and September 1986, 48 patients with advanced (stages III and IV) intermediate and high-grade non-Hodgkin's lymphoma (NHL) were treated with weekly CHOP (doxorubicin, vincristine, cyclophosphamide, and prednisolone), using reduced dosages of cyclophosphamide and doxorubicin. Low-dose oral maintenance chemotherapy was given for 2 years to those patients in remission. Twenty-seven patients (56%) of the evaluable 48 patients achieved a complete response and 12 patients (25%) had a partial response, for an overall response rate of 81%. The relapse-free survival for complete responders has been at a plateau of 67% at 16 months, and actuarial survival for complete responders has been 62%, with no deaths occurring beyond 43 months (survival plateau). One treatment-related death occurred, but toxicity was generally modest. The median time required from the start of weekly CHOP to complete response was only 5 weeks. Weekly CHOP can achieve results similar to those obtained by currently popular regimens utilizing a greater number of drugs at higher dosages.
Shimizu
K
K
Department of Medicine, Fujita Gakuen Health University, Aichi, Japan.
Hara
K
K
Kunii
A
A
D000206:Actuarial Analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone